NexaBiome

NexaBiomes patented technology enables bacteriophages to be covalently attached to a wide variety of substrates; this gives them enhanced stability for use in a variety of applications which address two of the worlds major challenges, antibiotic resistance and food supply and sustainability. By attaching specific bacteriophages to fish and animal feeds, we can reduce, augment or even substitute for antibiotics in the food chain. This lets us target both human and animal pathogens, such as E. coli, Listeria, Campylobacter, Salmonella, Streptococcus, Pseudomonas, Flavobacteria and others. As our bonded phage products can be stable for months or even years and are...

Probiotic feeds,antibiotic resistance,food wastage,zinc oxide replacement,formaldehyde replacement,aquaculture,poultry,microbiome,active packaging,veterinary health,tilapia,salmonids,shelf life extension,agriscience,mrsa,e.coli,pseudomonas,campylobacter,and listeria

Nexabiome operates in the Biotechnology research industry.

Nexabiome's revenue is 11m - 100m

Nexabiome has 11 - 50 employees.